Project Grant R01CA308205
Award Date 8/3/26
Completion Date 7/31/30
Dollars Obligated $647K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University a Project Grant totaling $2.47 million under the Cancer Biology Research program (CFDA 93.396) on August 18, 2025, with completion targeted for July 31, 2029. This grant supports fundamental research investigating the role of wild-type isocitrate dehydrogenase 1 (WT-IDH1) metabolism in reprogramming the tumor microenvironment of glioblastoma. The research encompasses both in vitro and in...
- The National Cancer Institute awarded The Washington University $659,087 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research targeting the NRF2 oxidative stress response pathway to sensitize head and neck squamous cell carcinoma (HNSCC) to immune checkpoint inhibitors. The research develops mechanistic understanding of how NRF2 pathway activation drives immune exclusion and resistance to anti-PD1 immunotherapy in HNSCC, which accounts for the sixth...
- The National Cancer Institute awarded The Washington University $399,829 on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to mechanistically characterize a novel dendritic cell-based immunotherapy for solid tumors. The project will investigate how engineered dendritic cells expressing a B7H3-specific chimeric antigen receptor fused to toll-like receptor 4 signaling domains can overcome tumor immune tolerance by efficiently capturing tumor antigens and cross-priming...
- The National Cancer Institute awarded The Washington University $155,500 for research identifying and characterizing mutation-induced alternative splicing events in cancer using multi-omics data, with an award date of June 1, 2026 under the Cancer Biology Research program (CFDA 93.396). The project aims to discover mutation-induced alternative splicing events, understand their functional relevance, and identify neoantigens arising from these events to advance cancer immunotherapy. The research...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University a Project Grant totaling $3,182,665 (Award Date: September 24, 2025; Completion Date: August 31, 2029) under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of natural killer (NK) cells in immune checkpoint therapy (ICT) of cancer. The research will elucidate the mechanisms by which NK cells constrain the effectiveness of ICT, evaluate the contribution of the NKG2D...
- The National Cancer Institute awarded The Washington University $623,616 on July 10, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to support development of PET imaging methods for detecting and quantifying CD163+ tumor-associated macrophages in head and neck cancer. The research addresses the role of tumor-associated macrophages (TAMs) in the tumor microenvironment, which coordinate angiogenesis, extracellular matrix remodeling, cancer cell proliferation,...
- The National Institutes of Health National Cancer Institute awarded The Washington University $399,829 under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, to conduct rational design of next-generation engineered T cells for enhanced cancer immunotherapy. The research addresses limited persistence of engineered T cells in cancer treatment by harnessing 4-1BB (CD137/TNFRSF9), a co-stimulatory molecule, through structure-informed protein design. Current 4-1BB chimeric...
- The National Cancer Institute awarded The Washington University $498,290 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate epigenetic regulation of premalignant states in cutaneous squamous cell carcinoma. The funded research defines the causes and consequences of KDM6A mislocalization in skin cancer through two primary aims. Aim 1 involves exome sequencing of banked human tumors to identify genomic correlates of KDM6A mislocalization, in...
- The National Institutes of Health National Cancer Institute awarded The Washington University $645,185 under the Cancer Treatment Research program (CFDA 93.395) on May 15, 2026, to develop and test a combination immunotherapy approach for glioblastoma. The recipient will conduct research on an "expand and pull" strategy combining long-acting interleukin-7 (IL-7) with oncolytic virus therapy to expand peripheral CD8+ T cells and recruit them into the glioblastoma tumor microenvironment....
- The National Cancer Institute awarded The Washington University $542,644 for Project Grant R01CA298938 on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395), a Project Grant assistance type. The award funds development and preclinical testing of radiation-guided antibody-drug conjugates (ADCs) targeting TAX-interacting protein 1 (TIP1) as a strategy to enhance non-small cell lung cancer (NSCLC) treatment. The research leverages a discovery that TIP1 is significantly...